Hunan Nucien Pharmaceutical Co., Ltd. (SHA:688189)

Market Cap	2.24B +22.6%
Revenue (ttm)	141.93M -46.1%
Net Income	-137.25M
EPS	-0.50
Shares Out	272.56M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,865,660
Average Volume	4,754,342
Open	8.07
Previous Close	8.15
Day's Range	7.97 - 8.12
52-Week Range	5.42 - 18.78
Beta	0.16
RSI	40.30
Earnings Date	Apr 24, 2026

About SHA:688189

Hunan Nucien Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research and development, production, and sale of chemical drugs in China. The company also focuses on the research, development, production, and sales of antiviral drugs, including influenza and infectious disease prevention and treatment drugs, as well as medicines for anti-influenza, malignant tumors, cardiovascular, antibiotics, antipyretics, pain relief, diabetes, analgesic, cerebrovascular, respiratory, and other pharmaceutical fields. Hunan Nucien Pharmaceuti...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 319
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688189

Financial Performance

In 2025, SHA:688189's revenue was 141.93 million, a decrease of -46.09% compared to the previous year's 263.28 million. Losses were -137.25 million, -61.54% less than in 2024.